Log in

Relevant bibliographies by topics / Antipsychotic drugs. Diabetes / Journal articles

To see the other types of publications on this topic, follow the link: Antipsychotic drugs. Diabetes.

Journal articles on the topic 'Antipsychotic drugs. Diabetes'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antipsychotic drugs. Diabetes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Taylor, David, Corina Young, Raadiyya Esop, Carol Paton, and Rebecca Walwyn. "Testing for diabetes in hospitalised patients prescribed antipsychotic drugs." British Journal of Psychiatry 185, no. 2 (2004): 152–56. http://dx.doi.org/10.1192/bjp.185.2.152.

Full text

Abstract:

BackgroundStudies using computer databases suggest that atypical antipsychotic agents are more likely to be associated with diabetes than are conventional drugs.AimsTo discover the extent of testing for diabetes mellitus in hospital in-patients prescribed antipsychotics.MethodPrescription charts were screened to identify patients prescribed antipsychotics. Case notes were then searched for evidence of testing for diabetes.ResultsIn all, 606 patients were prescribed antipsychotics, of whom 250 (41.3%) had evidence of prior testing for diabetes. Patients prescribed atypicals were 40% more likely

APA, Harvard, Vancouver, ISO, and other styles

2

Kessing, Lars Vedel, Anders Frøkjær Thomsen, Ulla Brasch Mogensen, and Per Kragh Andersen. "Treatment with antipsychotics and the risk of diabetes in clinical practice." British Journal of Psychiatry 197, no. 4 (2010): 266–71. http://dx.doi.org/10.1192/bjp.bp.109.076935.

Full text

Abstract:

BackgroundTreatment with antipsychotics seems to increase the risk of developing diabetes but the association is poorly characterised in clinical practice.AimsTo investigate and characterise the incidence of diabetes for people treated with antipsychotic medication in clinical practice.MethodThe study used the linkage of registers of all prescribed antipsychotics, antidiabetics and diagnoses of diabetes in Denmark during a period from 1996 to 2005 and identified all people treated with antipsychotics in Denmark and a random sample of about 30% of the total Danish population.ResultsIn total, 34

APA, Harvard, Vancouver, ISO, and other styles

3

Proietto, Joseph. "Diabetes and antipsychotic drugs." Australian Prescriber 27, no. 5 (2004): 118–19. http://dx.doi.org/10.18773/austprescr.2004.098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

M, Jagadeesan, Kiran Kumar R, and Justin Jacob Abraham. "A CASE STUDY ON SCHIZOPHRENIA INDUCED MULTIPLE COMORBIDITIES." Asian Journal of Pharmaceutical and Clinical Research 11, no. 6 (2018): 1. http://dx.doi.org/10.22159/ajpcr.2018.v11i6.23979.

Full text

Abstract:

Schizophrenia is a mental disorder characterized by abnormal social behavior which includes false beliefs, confusion, and auditory hallucination. Antipsychotic drugs therapy increases the risk of developing diabetes mellitus and coronary artery disease (CAD) in schizophrenic patients. Hence, we have planned for a systematic approach toward the management of comorbidities induced in schizophrenic patients. A case study was conducted in 42-year-old female patient diagnosed with schizophrenia along with Type-2 diabetes mellitus, hypothyroidism, diabetic retinopathy, diabetic nephropathy, systemic

APA, Harvard, Vancouver, ISO, and other styles

5

Livingstone, C., and H. Rampes. "Atypical antipsychotic drugs and diabetes." Practical Diabetes International 20, no. 9 (2003): 327–31. http://dx.doi.org/10.1002/pdi.552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Henderson, Valerie. "Atypical antipsychotic drugs and diabetes." Practical Diabetes International 20, no. 9 (2003): 331. http://dx.doi.org/10.1002/pdi.553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Abdelmawla, Nasser, and Alex J. Mitchell. "Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention." Advances in Psychiatric Treatment 12, no. 2 (2006): 100–109. http://dx.doi.org/10.1192/apt.12.2.100.

Full text

Abstract:

Cardiac safety of antipsychotic drugs continues to be a concern for both typical and atypical antipsychotics. Risk appears greatest in those with pre-existing cardiac disease but many patients may have occult cardiovascular disease. In addition, several drugs appear to increase the likelihood of diabetes and weight gain, which may have an additive adverse effect. On the basis of risk of sudden cardiac death and risk of QTc prolongation we suggest considering antipsychotics in two categories – higher and lower risk. Of most concern is the use of large cumulative doses of antipsychotics that are

APA, Harvard, Vancouver, ISO, and other styles

8

Bottai, T., P. Quintin, and E. Perrin. "Antipsychotics and the risk of diabetes: A general data review." European Psychiatry 20, S4 (2005): S349—S357. http://dx.doi.org/10.1016/s0924-9338(05)80190-7.

Full text

Abstract:

AbstractRecently, attention has focused on a potential link between schizophrenia and diabetes, with speculation that this potential associationis stronger in patients who are prescribed atypical antipsychotics. Pharmacoepidemiological studies can help to evaluate this potential association. Source data on the incidence of diabetes in patients treated with antipsychotics is available in the FDA MedWatch database, prescription claims databases and other patient registries. These data indicate that antipsychotic drugs may increase the risk of developing diabetes and that there may be an interact

APA, Harvard, Vancouver, ISO, and other styles

9

Tournier, M., A. Cougnard, B. Bégaud, A. Thiébaut, and H. Verdoux. "The Metabolic Impact of the Antipsychotic Drugs in Patients with Bipolar Disorder." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70490-0.

Full text

Abstract:

Objective:To assess the metabolic impact of adding an antipsychotic to a mood stabilizer or switching a mood stabilizer to an antipsychotic in patients with bipolar disorder.Methods:A retrospective fixed cohort study was conducted through the claims database of the French health care program for the self-employed workers. The study population consisted of 3.172 patients age 18 and over who were exposed to mood stabilizers (i.e. lithium, valproate) a 3 month-period in 2004 without dispensing of non-sedative antipsychotic, antidiabetic or lipid-lowering drugs. The outcome was the occurrence of a

APA, Harvard, Vancouver, ISO, and other styles

10

Ananth, Jambur, Smitha Kolli, Sarath Gunatilake, and Steven Brown. "Atypical antipsychotic drugs, diabetes and ethnicity." Expert Opinion on Drug Safety 4, no. 6 (2005): 1111–24. http://dx.doi.org/10.1517/14740338.4.6.1111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Holt, Richard I. G., and Robert C. Peveler. "Association between antipsychotic drugs and diabetes." Diabetes, Obesity and Metabolism 8, no. 2 (2006): 125–35. http://dx.doi.org/10.1111/j.1463-1326.2005.00495.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Currie, Olivia, Jonathan Williman, Dee Mangin, Bianca McKinnon-Gee, and Paul Bridgford. "Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design." BMJ Open 9, no. 2 (2019): e022984. http://dx.doi.org/10.1136/bmjopen-2018-022984.

Full text

Abstract:

ObjectiveNewer antipsychotics are increasingly prescribed off-label for non-psychotic ailments both in primary and secondary care settings, despite the purported risk of weight gain and development of type 2 diabetes mellitus. This study aims to determine any relationship between the development of clinically significant new-onset type 2 diabetes mellitus and novel antipsychotic use in New Zealand using hypnotic drugs as control.DesignA population-based clustered multiple baseline time series design.SettingRoutinely collected data from a complete national pharmaceutical database in New Zealand

APA, Harvard, Vancouver, ISO, and other styles

13

Manu, P., C. U. Correll, R. van Winkel, M. Wampers, and M. De Hert. "Prediabetes in patients treated with antipsychotic drugs." European Psychiatry 26, S2 (2011): 1164. http://dx.doi.org/10.1016/s0924-9338(11)72869-3.

Full text

Abstract:

BackgroundIn 2010, the American Diabetes Association (ADA) proposed that individuals with fasting glucose 100–125 mg/dl (5.6-6.9 mmol/l) or glucose 140–199 mg/dl (7.8–11.0 mmol/l) 2 hours after a 75 gm oral glucose tolerance test (OGGT) or hemoglobin A1c (A1c) 5.7–6.4% be classified as prediabetic to indicate a high risk for the development of diabetes.ObjectiveTo determine the prevalence of prediabetes in psychiatric patients receiving antipsychotics and to compare the clinical and metabolic features of patients with normal glucose tolerance, prediabetes and diabetes.MethodThe 2010 ADA criter

APA, Harvard, Vancouver, ISO, and other styles

14

Wilson, Carol. "Antipsychotic drugs and hyperglycemia risk in diabetes." Nature Reviews Endocrinology 5, no. 11 (2009): 584. http://dx.doi.org/10.1038/nrendo.2009.185.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Vigod, Simone N., Yona Lunsky, Virginie Cobigo, Andrew S. Wilton, Sarah Somerton, and Dallas P. Seitz. "Morbidity and mortality of women and men with intellectual and developmental disabilities newly initiating antipsychotic drugs." BJPsych Open 2, no. 2 (2016): 188–94. http://dx.doi.org/10.1192/bjpo.bp.116.002691.

Full text

Abstract:

BackgroundWhile up to 45% of individuals with intellectual and developmental disabilities (IDD) have a comorbid psychiatric disorder, and antipsychotics are commonly prescribed, gender differences in the safety of antipsychotics have rarely been studied in this population.AimsTo compare men and women with IDD on medical outcomes after antipsychotic initiation.MethodOur population-based study in Ontario, Canada, compared 1457 women and 1951 men with IDD newly initiating antipsychotic medication on risk for diabetes mellitus, hypertension, venous thromboembolism, myocardial infarction, stroke an

APA, Harvard, Vancouver, ISO, and other styles

16

Sivolap, Yuriy, and Anna Portnova. "Excessive use of antipsychotics as a global problem of clinical medicine." Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery), no. 5 (May 1, 2020): 9–16. http://dx.doi.org/10.33920/med-01-2005-01.

Full text

Abstract:

In recent decades in many regions of the world there has been an increase in prescribing antipsychotics, including for children and adolescents, and in many cases the drugs are used off label, in patients without diagnosis of schizophrenia and other psychoses and bipolar disorder or — in child and adolescent practice — without severe behavioral disorders. In addition, antipsychotics are often prescribed at excessive doses, and antipsychotic therapy is not accompanied by proper monitoring of physiological functions and laboratory parameters. The metabolic effects of antipsychotics contribute to

APA, Harvard, Vancouver, ISO, and other styles

17

AlDakheel, S. "Antipsychotic drugs in pregnancy." European Psychiatry 41, S1 (2017): S562. http://dx.doi.org/10.1016/j.eurpsy.2017.01.816.

Full text

Abstract:

BackgroundThere has been significant increase in prescription of antipsychotic medication in the community for females in childbearing age the problem is we do not have clear guidelines because we do not have a control group.ObjectivesTo evaluate maternal psychiatric, medical and perinatal outcomes associated with antipsychotic drugs in pregnancy.AimTo use wisdom when the risk is minimal for both mother and child.MethodWe study 3 pregnant women, one with a 6 years old, one with a 2 years old child and one still pregnant. We measure their blood sugar, blood pressure, fetal heart, movement, ultr

APA, Harvard, Vancouver, ISO, and other styles

18

Manu, P., C. U. Correll, M. Wampers, et al. "Dysmetabolic features of the overweight patients receiving antipsychotic drugs: A comparison with normal weight and obese subjects." European Psychiatry 29, no. 3 (2014): 179–82. http://dx.doi.org/10.1016/j.eurpsy.2012.12.001.

Full text

Abstract:

AbstractBackground:Extensive research indicates that obesity, defined by a body mass index (BMI) greater or equal to 30, is common in patients treated with antipsychotic drugs and is frequently associated with carbohydrate and lipid abnormalities leading to metabolic syndrome and diabetes. In contrast, the metabolic health of overweight patients (BMI = 25–29.9) without metabolic syndrome or diabetes has not been thoroughly investigated.Objective:To assess the metabolic health of overweight patients receiving antipsychotic drugs.Methods:We compared standard metabolic parameters (BMI; waist circ

APA, Harvard, Vancouver, ISO, and other styles

19

Smith, Greg. "How do antipsychotic drugs cause diabetes and obesity?" Obesity Research & Clinical Practice 7 (December 2013): e41. http://dx.doi.org/10.1016/j.orcp.2013.12.579.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Panariello, Fabio, Vincenzo De Luca, and Andrea de Bartolomeis. "Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies." Schizophrenia Research and Treatment 2011 (2011): 1–16. http://dx.doi.org/10.1155/2011/459284.

Full text

Abstract:

Excess body weight is one of the most common physical health problems among patients with schizophrenia that increases the risk for many medical problems, including type 2 diabetes mellitus, coronary heart disease, osteoarthritis, and hypertension, and accounts in part for 20% shorter life expectancy than in general population. Among patients with severe mental illness, obesity can be attributed to an unhealthy lifestyle, personal genetic profile, as well as the effects of psychotropic medications, above all antipsychotic drugs. Novel “atypical” antipsychotic drugs represent a substantial impr

APA, Harvard, Vancouver, ISO, and other styles

21

Linck, Viviane M., Ana P. Herrmann, Ângelo L. Piato, et al. "Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes." Evidence-Based Complementary and Alternative Medicine 2011 (2011): 1–7. http://dx.doi.org/10.1093/ecam/nep002.

Full text

Abstract:

Managing schizophrenia has never been a trivial matter. Furthermore, while classical antipsychotics induce extrapyramidal side effects and hyperprolactinaemia, atypical antipsychotics lead to diabetes, hyperlipidaemia, and weight gain. Moreover, even with newer drugs, a sizable proportion of patients do not show significant improvement. Alstonine is an indole alkaloid identified as the major component of a plant-based remedy used in Nigeria to treat the mentally ill. Alstonine presents a clear antipsychotic profile in rodents, apparently with differential effects in distinct dopaminergic pathw

APA, Harvard, Vancouver, ISO, and other styles

22

Firestone, Andrew. "Weight gain and diabetes with “second‐generation” antipsychotic drugs." Medical Journal of Australia 182, no. 12 (2005): 652–53. http://dx.doi.org/10.5694/j.1326-5377.2005.tb06860.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lipscombe, Lorraine L., Linda Lévesque, Andrea Gruneir, et al. "Antipsychotic Drugs and Hyperglycemia in Older Patients With Diabetes." Archives of Internal Medicine 169, no. 14 (2009): 1282. http://dx.doi.org/10.1001/archinternmed.2009.207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Davis, Vanessa, and Arlan L. Rosenbloom. "Metabolic effects of antipsychotic drugs." Pediatric Diabetes 7, no. 3 (2006): 176–86. http://dx.doi.org/10.1111/j.1399-543x.2006.00178.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rouillon, F., and F. Sorbara. "Schizophrenia and diabetes: Epidemiological data." European Psychiatry 20, S4 (2005): S345—S348. http://dx.doi.org/10.1016/s0924-9338(05)80189-0.

Full text

Abstract:

AbstractThe association of diabetes mellitus and mental illness, in particular, schizophrenia, has been remarked upon for over a century. Recentepidemiological studies have shown the age- and sex-matched prevalence of diabetes in patients with schizophrenia to be 1.5–2 times those in the general population. This difference is particularly noticeable in younger patients. The explanation for this finding probably resides in both environmental and biological factors. Patients with schizophrenia tend to be sedentary and have a poor diet, which are both known risk factors for diabetes. However, fam

APA, Harvard, Vancouver, ISO, and other styles

26

Atti, A. R., B. Ferrari Gozzi, G. Zuliani, et al. "A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia." International Psychogeriatrics 26, no. 1 (2013): 19–37. http://dx.doi.org/10.1017/s1041610213001658.

Full text

Abstract:

ABSTRACTBackground:In clinical practice, Second Generation Antipsychotics (SGAs) are often used as first-line treatment for the Behavioral and Psychological Symptoms of Dementia (BPSD) in older adults due to their fewer neurological adverse events and similar effectiveness compared with First Generation Antipsychotics (FGAs). SGAs, however, are associated with more severe metabolic side effects (weight gain, hyperglycemia, diabetes risk, and hyperlipidemia) than FGAs are. In general, older patients, especially those affected by dementia, are at increased risk for malnutrition, and tend to have

APA, Harvard, Vancouver, ISO, and other styles

27

Bughio, Abdul Hafeez, Shafak Ansari, Rajesh Kumar, Muhammad Hassan Sheikh, and Tarachand Devrajani. "Effect of atypical antipsychotics on blood glucose levels and HbA1c in patients of schizophrenia and bipolar disorder." Professional Medical Journal 28, no. 02 (2021): 158–64. http://dx.doi.org/10.29309/tpmj/2021.28.02.5189.

Full text

Abstract:

Objectives: To evaluate the effect of atypical antipsychotics on serum glucose levels and HbA1C in patients of schizophrenia and bipolar disorder. Study Design: Quasi-experimental study. Setting: Department of Neurology and Sir C. J Institute of Psychiatry LUMHS Jamshoro/Hyderabad. Period: Dec 2018-Dec 2019. Material & Methods: Total 360 participants of age more than 15 years of either gender presenting with psychiatric illness i.e. schizophrenia and bipolar disorder and prescribed same brand of antipsychotic drugs were included in the study. Fasting blood glucose (FBS), random blood gluco

APA, Harvard, Vancouver, ISO, and other styles

28

Citrome, Leslie, and Jan Volavka. "Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes." Journal of Clinical Psychiatry 66, no. 08 (2005): 1073–74. http://dx.doi.org/10.4088/jcp.v66n0818c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lamberti, J., J. Crilly, K. Maharaj, D. Olson, and O. Costea. "Prevalence of adult-onset diabetes among outpatients receiving antipsychotic drugs." Schizophrenia Research 60, no. 1 (2003): 360. http://dx.doi.org/10.1016/s0920-9964(03)80179-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Medak, Kyle D., Hesham Shamshoum, Willem T. Peppler, and David C. Wright. "GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia." American Journal of Physiology-Endocrinology and Metabolism 319, no. 6 (2020): E1101—E1111. http://dx.doi.org/10.1152/ajpendo.00309.2020.

Full text

Abstract:

Antipsychotic drugs cause rapid perturbations in glucose and lipid metabolism. In the present study we have demonstrated that cotreatment with glucagon-like peptide 1 (GLP1) receptor agonists, such as liraglutide, protects against metabolic dysregulation caused by the antipsychotic drug olanzapine. These findings suggest that pharmacological targeting of the GLP1 receptor could be an effective adjunct approach to mitigate the harmful acute metabolic side effects of antipsychotic drugs.

APA, Harvard, Vancouver, ISO, and other styles

31

Bushe, Chris, and Brian Leonard. "Association between atypical antipsychotic agents and type 2 diabetes: Review of prospective clinical data." British Journal of Psychiatry 184, S47 (2004): s87—s93. http://dx.doi.org/10.1192/bjp.184.47.s87.

Full text

Abstract:

BackgroundMost evidence suggesting an association between schizophrenia, antipsychotic medications and diabetes has been based on retrospective studies not controlled for important confounders.AimsTo compare diabetogenic risk between antipsychotic medications; and to describe the limitations of current prospective data-sets.MethodSystematic review of prospective clinical data.ResultsNo difference in the incidence of glycaemic abnormalities between placebo cohorts and antipsychotic medication cohorts was identified. No significant difference between any of the antipsychotic medications studied

APA, Harvard, Vancouver, ISO, and other styles

32

Molitch, Mark E. "Dopamine agonists and antipsychotics." European Journal of Endocrinology 183, no. 3 (2020): C11—C13. http://dx.doi.org/10.1530/eje-20-0607.

Full text

Abstract:

There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. The psychiatric benefits of antipsychotic agents involve blocking the D2 and other dopamine receptors but th

APA, Harvard, Vancouver, ISO, and other styles

33

Morrato, E. H., J. W. Newcomer, S. Kamat, O. Baser, J. Harnett, and B. Cuffel. "Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes." Diabetes Care 32, no. 6 (2009): 1037–42. http://dx.doi.org/10.2337/dc08-1720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Spoelstra, José A., Ronald P. Stolk, Dan Cohen, et al. "Antipsychotic Drugs May Worsen Metabolic Control in Type 2 Diabetes Mellitus." Journal of Clinical Psychiatry 65, no. 5 (2004): 674–78. http://dx.doi.org/10.4088/jcp.v65n0512.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Erkens, JA, K. Pugner, P. Lapuerta, and RMC Herings. "DB1 ASSOCIATION BETWEEN ANTIPSYCHOTIC DRUGS AND DIABETES MELLITUS: A PHARMO STUDY." Value in Health 7, no. 6 (2004): 648. http://dx.doi.org/10.1016/s1098-3015(10)65670-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Matchett, J. L., N. B. Fishman, S. B. Radmaker, and D. E. Casey. "The effect of atypical antipsychotic drugs in patients with preexisting diabetes." Schizophrenia Research 60, no. 1 (2003): 362. http://dx.doi.org/10.1016/s0920-9964(03)80185-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Sumiyoshi, Tomiki, Ajanta Roy, A. Elif Anil, Karu Jayathilake, Aygun Ertugrul, and Herbert Y. Meltzer. "A Comparison of Incidence of Diabetes Mellitus Between Atypical Antipsychotic Drugs." Journal of Clinical Psychopharmacology 24, no. 3 (2004): 345–48. http://dx.doi.org/10.1097/01.jcp.0000126668.67820.00.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

de Hert, M., B. Falissard, M. Mauri, K. Shaw, and T. Wetterling. "Epidemiological Study for the Evaluation of Metabolic Disorders in Patients with Schizophrenia: The Meteor Study." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)71367-7.

Full text

Abstract:

A large, observational, multinational cross-sectional pharmacoepidemiological study was performed to determine the prevalence of diabetes and other metabolic disorders in patients with schizophrenia receiving atypical antipsychotic drugs in Europe.The study included adult outpatients with schizophrenia (DSM-IV-TR) treated for at least three months by an antipsychotic drug. Patients treated with classical or atypical antipsychotic drugs were recruited into two parallel strata (ratio of 1:3). A fasting blood sample was taken and height, weight, waist and hip circumference and blood pressure meas

APA, Harvard, Vancouver, ISO, and other styles

39

Carpéné, Christian, Francisco Les, Josep Mercader, et al. "Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control." Pharmaceuticals 13, no. 3 (2020): 41. http://dx.doi.org/10.3390/ph13030041.

Full text

Abstract:

Treatment with several antipsychotic drugs exhibits a tendency to induce weight gain and diabetic complications. The proposed mechanisms by which the atypical antipsychotic drug olanzapine increases body weight include central dysregulations leading to hyperphagia and direct peripheral impairment of fat cell lipolysis. Several investigations have reproduced in vitro direct actions of antipsychotics on rodent adipocytes, cultured preadipocytes, or human adipose tissue-derived stem cells. However, to our knowledge, no such direct action has been described in human mature adipocytes. The aim of t

APA, Harvard, Vancouver, ISO, and other styles

40

Milano, Walter, Michele De Rosa, Luca Milano, and Anna Capasso. "Antipsychotic Drugs Opposite to Metabolic Risk: Neurotransmitters, Neurohormonal and Pharmacogenetic Mechanisms Underlying with Weight Gain and Metabolic Syndrome." Open Neurology Journal 7, no. 1 (2013): 23–31. http://dx.doi.org/10.2174/1874205x01307010023.

Full text

Abstract:

Important sources of metabolic diseases such as obesity and metabolic syndrome are significantly more prevalent in patients treated with antipsychotic drugs than the general population and they not only reduce the quality of life but also significantly reduce the life expectancy, being important risk factors for cardiovascular disease. The pathogenic mechanisms underlying these events are not entirely clear they are complex and multi-determined or not tied to a single defining event. In this review we examine the literature on the interactions of antipsychotic drugs with neurotransmitters in t

APA, Harvard, Vancouver, ISO, and other styles

41

Fleischhacker, W. Wolfgang, Cynthia O. Siu, Robert Bodén, Elizabeth Pappadopulos, Onur N. Karayal, and René S. Kahn. "Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial." International Journal of Neuropsychopharmacology 16, no. 5 (2013): 987–95. http://dx.doi.org/10.1017/s1461145712001241.

Full text

Abstract:

Abstract Available data on antipsychotic-induced metabolic risks are often constrained by potential confounding effects due to prior antipsychotic treatment. In this study, we assessed the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or ziprasidone) in first-episode, partially antipsychotic-naive patients with schizophrenia in the European first-episode schizophrenia trial (EUFEST). Overall baseline prevalence of metabolic syndrome (MetS) was 6.0%, with similar rates

APA, Harvard, Vancouver, ISO, and other styles

42

Taylor, David, Corina Young, Radia Mohamed, Carol Paton, and Rebecca Walwyn. "Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs." Journal of Psychopharmacology 19, no. 2 (2005): 182–86. http://dx.doi.org/10.1177/0269881105049039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Bellantuono, Cesario, Luigi Tentoni, and Pietro Donda. "Antipsychotic drugs and risk of type 2 diabetes: An evidence-based approach." Human Psychopharmacology: Clinical and Experimental 19, no. 8 (2004): 549–58. http://dx.doi.org/10.1002/hup.628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Holt, R. I. G., and R. C. Peveler. "Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria." Diabetologia 49, no. 7 (2006): 1467–76. http://dx.doi.org/10.1007/s00125-006-0279-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Nasrallah, Henry A. "Metabolic Findings From the CATIE Trial and Their Relation to Tolerability." CNS Spectrums 11, S7 (2006): 32–39. http://dx.doi.org/10.1017/s1092852900026663.

Full text

Abstract:

AbstractThe overall effectiveness of antipsychotics for the management of schizophrenia is restricted by their side-effect profiles, particularly over an extended treatment period. Intolerable side effects can reduce patient adherence to medication and often lead to treatment discontinuation. Some side effects that result from antipsychotic use are precursors to the metabolic syndrome, which is prevalent among individuals with schizophrenia and represents a significant source of cardiovascular risk. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study ass

APA, Harvard, Vancouver, ISO, and other styles

46

Prifti, A., V. Qemalli, and L. Zikaj. "Monitoring of biochemicals changes in antipsychotics and anti-depressive therapy." European Psychiatry 33, S1 (2016): S339. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1187.

Full text

Abstract:

ObjectiveBiochemical changes in treatment of schizophrenic and bipolar disorders, in Albanian patients, with atypical antipsychotic and anti-depressive drugs. Some of the adverse effects related to their use are hyperlipidemia, hepatic enzymes, type 2 diabetes and CK level, which may result in development of metabolic syndrome. This study aimed to investigate a possible increase of biochemical parameters, in patients with schizophrenia and bipolar disorders treated with atypical antipsychotic and antidepressive drugs (Olanzapin, Risperidon, Clozapin, Antidepresiv triciclik, SSRI, SNRI).Methods

APA, Harvard, Vancouver, ISO, and other styles

47

Kwok, Jeffrey SS, and Thomas YK Chan. "Recurrent Heat-Related Illnesses During Antipsychotic Treatment." Annals of Pharmacotherapy 39, no. 11 (2005): 1940–42. http://dx.doi.org/10.1345/aph.1g130.

Full text

Abstract:

OBJECTIVE To report a case of recurrent heat-related illnesses associated with the use of benzhexol, chlorpromazine, and zuclopenthixol decanoate. CASE SUMMARY During the summer of 2004, a 48-year-old man with a history of diabetes mellitus and schizophrenia was twice admitted to the hospital because of heat-related illnesses. On both occasions, he had been working under the sun in an open car park. His medications included benzhexol 2 mg twice daily, chlorpromazine 650 mg at bedtime, and zuclopenthixol decanoate intramuscular injection 600 mg every 4 weeks. In the first admission, the clinica

APA, Harvard, Vancouver, ISO, and other styles

48

Allard, Lucie, Frédérique Albarel, Jérôme Bertherat, et al. "Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma." European Journal of Endocrinology 183, no. 2 (2020): 221–31. http://dx.doi.org/10.1530/eje-20-0125.

Full text

Abstract:

Context In patients treated with antipsychotics, the rare occurrence of a macroprolactinoma represents a therapeutic challenge. Objective Our aim was to evaluate the efficacy and psychiatric safety of dopamine agonists (DAs) prescribed for large macroprolactinomas in patients with psychosis treated with antipsychotics. Design This was a multicenter (France and Belgium) retrospective study. Patients Eighteen patients treated with antipsychotics were included. Results Under DA, median PRL levels decreased from 1247 (117–81 132) to 42 (4–573) ng/mL (P = 0.008), from 3850 (449–38 000) to 141 (60–6

APA, Harvard, Vancouver, ISO, and other styles

49

Lean, M. E. J., and F. G. Pajonk. "Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes." Diabetes Care 26, no. 5 (2003): 1597–605. http://dx.doi.org/10.2337/diacare.26.5.1597.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

van Keulen, Kris, Paul D. van der Linden, Patrick C. Souverein, Eibert R. Heerdink, Antoine C. G. Egberts, and Wilma Knol. "Risk of Hospitalization for Hypoglycemia in Older Patients with Diabetes Using Antipsychotic Drugs." American Journal of Geriatric Psychiatry 23, no. 11 (2015): 1144–53. http://dx.doi.org/10.1016/j.jagp.2015.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!